pituitary axis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-27 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
=== Transport === Like most of northwest London, Brent is served extensively by the London Underground. 21 tube stations are located in Brent, all served by either the Metropolitan, Jubilee, Bakerloo or Piccadilly Lines. All of them are surface level, with the exception of Kilburn Park tube station in the southeast of the borough. This number is the second highest of all London boroughs behind Westminster, which has 32 stations within its boundaries. The numerous London Underground, London Overground and National Rail stations in the borough are:
=== Hydrogenation === Hydrogenation is achieved by introducing hydrogen to the unsaturated compounds under high pressure in the presence of heterogeneous catalysts, such as finely divided nickel. This reaction converts benzene into cyclohexane. Benzene derivatives are also converted into their respective saturated equivalents. Whereas alkenes can be hydrogenated near room temperatures, benzene and its derivatives are more reluctant substrates, requiring temperatures exceeding 100 °C for hydrogenation to occur. This reaction is practiced on an industrial scale. Typically, benzene is fully saturated into cyclohexane during hydrogenation. However, with the right conditions, benzene can be partially-hydrogenated to give cyclohexene or cyclohexadienes. A similar reaction is the Birch reduction, which is a non-catalytic process that converts benzene into cyclohexadiene.
== History == The concept of hydrogen bonding once was challenging. Linus Pauling credits T. S. Moore and T. F. Winmill with the first mention of the hydrogen bond, in 1912. Moore and Winmill used the hydrogen bond to account for the fact that trimethylammonium hydroxide is a weaker base than tetramethylammonium hydroxide. The description of hydrogen bonding in its better-known setting, water, came some years later, in 1920, from Latimer and Rodebush. In that paper, Latimer and Rodebush cited the work of a fellow scientist at their laboratory, Maurice Loyal Huggins, saying, "Mr. Huggins of this laboratory in some work as yet unpublished, has used the idea of a hydrogen kernel held between two atoms as a theory in regard to certain organic compounds."
Sources: en.wikipedia.org
==== "Stolen election" conspiracy theories ==== Following Trump's victory, some Harris supporters on X shared election denial conspiracy theories, claiming that millions of ballots were "left uncounted" and there being something "not right" with the election. Such posts falsely claiming Trump "stole" the election peaked at noon the day after at 94,000 posts per hour, with many receiving amplification and gaining over a million views each. According to Gordon Crovitz, the CEO of the media rating system NewsGuard, the phrase "Trump cheated" received 92,100 mentions on the platform from midnight until the Wednesday morning after. Besides the claims from Harris's supporters, some Trump supporters baselessly claimed the disparity between other years, the 2020 election, and a then-incomplete 2024 voting total indicated voter fraud in the 2020 election. One major "basis" these false claims were founded upon was a claim that Biden won 20 million more votes in his prior election bid than Harris had in hers, at the time. American journalist and conspiracy theorist Wayne Madsen commented on Threads: "I'm beginning to believe our election was massively hacked just like happened a few weeks ago in the Republic of Georgia." At the time these claims were disseminated, votes were still being counted in many states. An estimate around the time using the Associated Press vote percentage total found that 16.2 million votes across 20 states and D.C. had yet to be counted.
=== Works cited === Army Techniques Publication 7-100.3: Chinese Tactics (PDF). Washington, D.C.: Headquarters, United States Army. 2021. ISBN 9798457607118. Goldstein, Melvyn C. (1997). The Snow Lion and the Dragon: China, Tibet, and the Dalai Lama. University of California Press. ISBN 978-0-520-21254-1. International Institute for Strategic Studies (12 February 2025). The Military Balance 2025. London: Routledge. doi:10.4324/9781003630760. ISBN 978-1-003-63076-0. Kaufman, Alison A.; Mackenzie, Peter W. (2009). The Culture of the Chinese People's Liberation Army (Report). Marine Corps Intelligence Activity. Archived from the original on 23 June 2024. Retrieved 23 June 2024. Pollpeter, Kevin; Allen, Kenneth W., eds. (14 June 2012). The PLA as Organization v2.0 (Report). China Aerospace Studies Institute. Saunders, Phillip C.; Ding, Arthur S.; Scobell, Andrew; Yang, Andrew N.D.; Joel, Wuthnow, eds. (2019). Chairman Xi Remakes the PLA: Assessing Chinese Military Reforms. Washington, D.C.: National Defense University Press. ISBN 978-1070233420. International Institute for Strategic Studies (2025). The Military Balance 2025. London: Routledge. ISBN 978-1-041-04967-8.
=== Postpartum === If the baby and mother survived the term of the pregnancy, childbirth was then the next step. The tools provided for birth were: towels to catch the blood, a container for the placenta, a pregnancy sash to support the belly, and an infant swaddling wrap. With these tools, the baby was born, cleaned, and swaddled; however, the mother was then immediately the focus of the doctor to replenish her qi. In his writings, Cheng Maoxian places a large amount of emphasis on the Four Diagnostic methods to deal with postpartum issues and instructs all physicians to "not neglect any [of the four methods]". The process of birthing was thought to deplete a woman's blood level and qi so the most common treatments for postpartum were food (commonly garlic and ginseng), medicine, and rest. This process was followed up by a month check-in with the physician, a practice known as zuo yuezi.
Sources: en.wikipedia.org
=== Hormones === Urine pregnancy test ― detects human chorionic gonadotropin in urine Urine cortisol ― used to investigate disorders of the adrenal glands Urine metanephrines ― used to help diagnose some rare tumours
=== Development of iron metallurgy === Iron is one of the elements undoubtedly known to the ancient world. It has been worked, or wrought, for millennia. However, iron artefacts of great age are much rarer than objects made of gold or silver due to the ease with which iron corrodes. The technology developed slowly, and even after the discovery of smelting it took many centuries for iron to replace bronze as the metal of choice for tools and weapons.
Peerschke EI, Ghebrehiwet B. Human blood platelets possess specific binding sites for C1q. J. Immunol. 1987;138:1537–41. Peerschke EI, Ghebrehiwet B. Identification and partial characterization of human platelet C1q binding sites. J. Immunol. 1988;141: 3505–11. Peerschke EI, Reid KB, Ghebrehiwet B. Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med. 1993;178:579–87. Peerschke EI, Reid KB, Ghebrehiwet B. Identification of a novel 33-kDa C1q-binding site on human blood platelets. J. Immunol. 1994;152:5896–901.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.